Literature DB >> 20346055

Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy.

Deepak Batura1, G Gopal Rao, Peder Bo Nielsen.   

Abstract

OBJECTIVE: To determine the prevalence of antimicrobial resistance in intestinal flora of patients undergoing transrectal ultrasonography (TRUS)-guided prostate biopsies (TGB) and to examine if this information is useful in selecting appropriate antimicrobial agents for prophylaxis and treatment of biopsy-associated infections. PATIENTS AND METHODS: In 2007 and 2008, rectal swabs were cultured from patients before undergoing TGB. Antimicrobial sensitivity of coliforms to amikacin, ciprofloxacin and coamoxiclav was determined. Laboratory records were used to identify patients who had bacteraemia or significant bacteriuria within 30 days of the TGB and the antimicrobial sensitivity pattern of these organisms were compared to those from the rectal swab.
RESULTS: Of 592 patients who had TGB, 445 (75.1%) had a rectal swab beforehand; 0.2%,10.6% and 13.3% of the coliforms were resistant to amikacin, ciprofloxacin and coamoxiclav, respectively. After TGB, six patients presented with urinary tract infections (UTI) and two with bacteraemia. All the infections were caused by coliforms except one UTI which was caused by ciprofloxacin-sensitive Pseudomonas aeruginosa. The blood culture isolates were sensitive to amikacin but resistant to ciprofloxacin and coamoxiclav. All the coliforms in the urine were resistant to ciprofloxacin but sensitive to coamoxiclav. Urine isolates were not tested for amikacin sensitivity. There was a strong correlation between the antimicrobial sensitivity of the coliforms from the rectal swabs and those cultured from urine or blood in both patients for amikacin, six of eight for ciprofloxacin and seven of eight for coamoxiclav.
CONCLUSIONS: Our study shows that in the coliforms in the bowel flora of our local population there is a relatively high level of resistance to ciprofloxacin and coamoxiclav, and very low level of resistance to amikacin. As there was a strong correlation between the antimicrobial sensitivity of organisms causing infections after TGB and those isolated from the rectal swabs, we conclude that rectal swab cultures before TGB provide useful evidence for selecting appropriate antimicrobials for prophylaxis and treatment of TGB-associated infections.
© 2010 THE AUTHORS. JOURNAL COMPILATION © 2010 BJU INTERNATIONAL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20346055     DOI: 10.1111/j.1464-410X.2010.09294.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  31 in total

1.  Infection: prostate biopsy-infection and prior fluoroquinolone exposure.

Authors:  Michael A Liss
Journal:  Nat Rev Urol       Date:  2011-10-11       Impact factor: 14.432

2.  Infective complications in patients after transrectal ultrasound-guided prostate biopsy and the role of ciprofloxacin resistant Escherichia coli colonization in rectal flora.

Authors:  Mustafa Bilal Hamarat; Fatih Tarhan; Rahim Horuz; Gülfem Akengin Öcal; Mehmet Kutlu Demirkol; Alper Kafkaslı; Özgür Yazıcı
Journal:  Turk J Urol       Date:  2017-05-03

3.  Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer.

Authors:  Andre C King; Andrew Livermore; Timo A J Laurila; Wei Huang; David F Jarrard
Journal:  Urol Oncol       Date:  2011-08-03       Impact factor: 3.498

Review 4.  Prostate MRI and transperineal TRUS/MRI fusion biopsy for prostate cancer detection: clinical practice updates.

Authors:  Eugenio Martorana; Giacomo Maria Pirola; Maria Cristina Aisa; Pietro Scialpi; Aldo Di Blasi; Giovanni Saredi; Alfredo D'Andrea; Stefano Signore; Riccardo Grisanti; Michele Scialpi
Journal:  Turk J Urol       Date:  2019-07-01

5.  Screening rectal culture to identify fluoroquinolone-resistant organisms before transrectal prostate biopsy: do the culture results between office visit and biopsy correlate?

Authors:  Michael A Liss; Kristen K Nakamura; Rachel Meuleners; Surendra B Kolla; Atreya Dash; Ellena M Peterson
Journal:  Urology       Date:  2013-07       Impact factor: 2.649

6.  Rapid Identification of Rectal Multidrug-resistant Escherichia coli Before Transrectal Prostate Biopsy.

Authors:  Veronika L Tchesnokova; Linda L Ottley; Kyoko Sakamoto; Joshua Fierer; Evgeni Sokurenko; Michael A Liss
Journal:  Urology       Date:  2015-08-20       Impact factor: 2.649

7.  Preoperative urine culture is unnecessary in asymptomatic men prior to prostate needle biopsy.

Authors:  David Z Qi; Kathleen Lehman; Kalyan Dewan; Girish Kirimanjeswara; Jay D Raman
Journal:  Int Urol Nephrol       Date:  2017-11-23       Impact factor: 2.370

8.  Cephalosporins periprostatic injection: are really effective on infections following prostate biopsy?

Authors:  Gianna Pace; Luca Carmignani; Carlo Marenghi; Gabriella Mombelli; Giorgio Bozzini
Journal:  Int Urol Nephrol       Date:  2012-03-22       Impact factor: 2.370

9.  Comparison of broth enhancement to direct plating for screening of rectal cultures for ciprofloxacin-resistant Escherichia coli.

Authors:  Michael A Liss; Kristen K Nakamura; Ellena M Peterson
Journal:  J Clin Microbiol       Date:  2012-11-14       Impact factor: 5.948

10.  Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy.

Authors:  Michael A Liss; Ellena M Peterson; Brian Johnston; Kathryn Osann; James R Johnson
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.